Results 91 to 100 of about 186,499 (128)
Study of Intraventricular Cerliponase Alfa for CLN2 Disease [PDF]
Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of ...
Jonathan P. Dyke +2 more
exaly +6 more sources
Cerliponase alfa is an orphan drug approved for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).Our goal was to assess the cost-effectiveness of cerliponase alfa in patients with CLN2 in the socioeconomic context of the Republic of Serbia in contrast to symptomatic therapy.For this study, a forty-year horizon and the ...
Miloš N Milosavljević +2 more
exaly +4 more sources
Extracellular aggregation of amyloid-beta (Aβ) in the brain plays a central role in the onset and progression of Alzheimer's disease (AD). Moreover, intraneuronal accumulation of Aβ via oligomer internalization might play an important role in the progression of AD.
Banu Cahide Tel +2 more
exaly +6 more sources

